BAYN Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. It has a commercial agreement with Neste to Jointly scale newgold winter canola for biofuels production. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Bayer (ETR: BAYN)
›
Bayer (ETR: BAYN) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 87,775 employees.
The shares were at 54.08 EUR on 20 November 2026, up 92.5% over 52 weeks. Its 52-week range is 26.64 EUR to 57.84 EUR: the price is 6.5% below the high and 103.0% above the low.
Its market capitalisation is 53.72B EUR. It pays a dividend yielding 0.20% (it pays out 162% of its earnings), against a median of 2.43% among the dividend payers in that peer group.
Bayer reports return on equity of -14.0%, an operating margin of 16.5% and revenue up 4.1% year over year.
Its debt exceeds its cash by 30.82B EUR, a debt-to-equity ratio of 1.40. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 18 analysts cover the stock, with an average rating of Buy; their mean price target of 60.58 EUR is 12.0% above the current price. The next earnings report is expected on 24 February 2027.